What is it about?
Lysophosphatidic acid (LPA) is a molecule that activates LPA1 receptors, which are found in high levels in breast cancer. This activation helps cancer cells grow, survive, spread, and form new blood vessels. Blocking LPA1 signaling with small molecules could help treat breast cancer. Researchers designed new compounds called 1,2,4-triazoles and 1,3,4-oxadiazoles to inhibit LPA1 receptors. They tested these compounds on breast cancer cells (MCF-7) to see how well they stopped cancer cell growth. The effective compounds were also tested for their ability to cause cancer cell death, reduce cell movement, and block the formation of new blood vessels. The results showed that compounds BI-4 and OX-1 effectively killed cancer cells, with IC50 values of 138μM and 83.25μM, respectively. These compounds also reduced cancer cell movement and increased cell death. They lowered the levels of LPA1 protein and genes involved in blood vessel formation in the cancer cells. Additionally, these compounds interacted well with the LPA1 receptor and were stable in simulations. Overall, BI-4 and OX-1 show promise as potential treatments for breast cancer by targeting the LPA1 receptor.
Featured Image
Why is it important?
LPA1 Receptors and Breast Cancer: LPA1 receptors, which are highly expressed in breast cancer, promote cancer cell growth, survival, spread, and blood vessel formation. New Compounds: Researchers created 1,2,4-triazoles and 1,3,4-oxadiazoles to block LPA1 receptors. Testing and Results: Compounds BI-4 and OX-1 were effective in killing breast cancer cells, reducing cell movement, and causing cell death. They also lowered levels of LPA1 protein and related genes. Potential Treatments: BI-4 and OX-1 show promise as treatments for breast cancer by targeting the LPA1 receptor.
Perspectives
This research offers a promising approach to breast cancer treatment by targeting LPA1 receptors, which are key players in cancer cell growth and spread. By developing new compounds, specifically 1,2,4-triazoles and 1,3,4-oxadiazoles, researchers have taken significant steps in blocking these receptors. The compounds BI-4 and OX-1 have shown strong potential in laboratory tests, effectively killing cancer cells, reducing their movement, and inducing cell death. Additionally, these compounds were able to lower the levels of LPA1 protein and associated genes that contribute to cancer progression. The successful interaction and stability of these compounds with the LPA1 receptor further highlight their potential as future breast cancer treatments. This work opens new avenues for targeted therapy, which could lead to more effective and specific treatments for patients.
Dr Gurubasavaraj V Pujar
JSS college of Pharmacy, JSS University, Mysuru, Karnataka, India 570015
Read the Original
This page is a summary of: New LPA1 receptor modulators: Design, synthesis, in-silico, and anticancer studies of triazole and oxadiazole analogs, Journal of Molecular Structure, January 2024, Elsevier,
DOI: 10.1016/j.molstruc.2023.136672.
You can read the full text:
Contributors
The following have contributed to this page
